M&A

Viking Therapeutics (NASDAQ: VKTX): The Last Independent Metabolic Challenger

From Clinical Contender to Commercial Platform or a Multi-Billion-Dollar Takeout

Dec 18, 2025 • AT Investment Research, The M&A Hunter, and Biotech Distilled

From Pipeline to Platform: Viking Therapeutics's (NASDAQ: VKTX) Metabolic Inflection Point

A Phase 3-ready disruptor with billion-dollar optionality and one of the cleanest balance sheets in biotech.

Nov 14, 2025 • AT Investment Research

Moderna Inc. (NASDAQ: MRNA) at $27: The Last Independent mRNA Powerhouse — Deep Value Before the Re-Rating or Acquisition

High burn, low expectations, and a $7.5B cash floor — Moderna now trades like pure optionality. The next five years decide if it’s a biotech turnaround…

Nov 3, 2025 • AT Investment Research

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Alpha Talon Investment Research

M&A